Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer: A meta-analysis and review of current literature

Research output: Contribution to journal › Review › Research › peer-review

Standard

Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer : A meta-analysis and review of current literature. / Christensen, Tine Nøhr; Andersen, Per Kragh; Langer, Seppo W.; Fischer, Barbara Malene Bjerregaard.

In: Diagnostics, Vol. 11, No. 2, 174, 2021.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Christensen, TN, Andersen, PK, Langer, SW & Fischer, BMB 2021, 'Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer: A meta-analysis and review of current literature', Diagnostics, vol. 11, no. 2, 174. https://doi.org/10.3390/diagnostics11020174

APA

Christensen, T. N., Andersen, P. K., Langer, S. W., & Fischer, B. M. B. (2021). Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer: A meta-analysis and review of current literature. Diagnostics, 11(2), [174]. https://doi.org/10.3390/diagnostics11020174

Vancouver

Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer: A meta-analysis and review of current literature. Diagnostics. 2021;11(2). 174. https://doi.org/10.3390/diagnostics11020174

Author

Christensen, Tine Nøhr ; Andersen, Per Kragh ; Langer, Seppo W. ; Fischer, Barbara Malene Bjerregaard. / Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer : A meta-analysis and review of current literature. In: Diagnostics. 2021 ; Vol. 11, No. 2.

Bibtex

@article{1fe6a70474044a0b93369e3db8704777,
title = "Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer: A meta-analysis and review of current literature",
abstract = "Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed{\textregistered}, Cochrane, and Embase{\textregistered} were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax ) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00–4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99–4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17–1.91); PFS: HR: 1.24 (95% CI: 0.94–1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.",
keywords = "FDG–PET/CT, Metabolic tumor volume, Prognosis, Small cell lung cancer, SUV",
author = "Christensen, {Tine N{\o}hr} and Andersen, {Per Kragh} and Langer, {Seppo W.} and Fischer, {Barbara Malene Bjerregaard}",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/diagnostics11020174",
language = "English",
volume = "11",
journal = "Diagnostics",
issn = "2075-4418",
publisher = "MDPI AG",
number = "2",

}

RIS

TY - JOUR

T1 - Prognostic value of18 f–fdg–pet parameters in patients with small cell lung cancer

T2 - A meta-analysis and review of current literature

AU - Christensen, Tine Nøhr

AU - Andersen, Per Kragh

AU - Langer, Seppo W.

AU - Fischer, Barbara Malene Bjerregaard

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax ) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00–4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99–4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17–1.91); PFS: HR: 1.24 (95% CI: 0.94–1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

AB - Many studies have suggested a prognostic value of one or several positron emission tomography (PET) parameters in patients with small cell lung cancer (SCLC). However, studies are often small, and there is a considerable interstudy disagreement about which PET parameters have a prognostic value. The objective of this study was to perform a review and meta-analysis to identify the most promising PET parameter for prognostication. PubMed®, Cochrane, and Embase® were searched for papers addressing the prognostic value of any PET parameter at any treatment phase with any endpoint in patients with SCLC. Pooled hazard ratios (HRs) were calculated by a random effects model for the prognostic value of the baseline maximum standardized uptake value (SUVmax ) and metabolic tumor volume (MTV). The qualitative analysis included 38 studies, of these, 19 studies were included in the meta-analyses. The pooled results showed that high baseline MTV was prognostic for overall survival (OS) (HR: 2.83 (95% confidence interval [CI]: 2.00–4.01) and progression-free survival (PFS) (HR: 3.11 (95% CI: 1.99–4.90)). The prognostic value of SUVmax was less pronounced (OS: HR: 1.50 (95% CI: 1.17–1.91); PFS: HR: 1.24 (95% CI: 0.94–1.63)). Baseline MTV is a strong prognosticator for OS and PFS in patients with SCLC. MTV has a prognostic value superior to those of other PET parameters, but whether MTV is superior to other prognosticators of tumor burden needs further investigation.

KW - FDG–PET/CT

KW - Metabolic tumor volume

KW - Prognosis

KW - Small cell lung cancer

KW - SUV

U2 - 10.3390/diagnostics11020174

DO - 10.3390/diagnostics11020174

M3 - Review

C2 - 33530446

AN - SCOPUS:85117066143

VL - 11

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 2

M1 - 174

ER -

ID: 291241711